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Abstract. 
Although Wuchereria bancrofti (Wb), the causative agent of lymphatic filariasis, is endemic throughout Mali, the 
prevalence of Wb microfilaremia (Mf) can vary widely between villages despite similar prevalence of infection as 
assessed by circulating antigen. To examine this variation, cross-sectional data obtained during screening prior to an 
interventional study in two neighboring villages in Mali were analyzed. The overall prevalence of Wb, as assessed 
by Wb Cag (circulating antigen), was 50.3% among 373 participants, aged 14-65. Wb Mf-positive and negative 
individuals appeared randomly distributed across the two villages (Moran’s I spatial statistic = -0.01, Z score = 0.1, 
P > 0.05). Among the 187 subjects positive for Wb CAg, 117 (62.5%) had detectable Mansonella perstans 
microfilaremia (Mp Mf) and 64(34.2%) had detectable Wb microfilaremia. The prevalence of Mp microfilaremia 
was 73.4% in the Wb Mf-positive group (as compared to 56.9% in the Wb Mf-negative group; p = 0.01), and 
median Wb Mf load was increased in co-infected subjects (267 Mf/ml vs 100 Mf/ml; p<0.001). In multivariate 
analysis, village of residence, Mp Mf positivity and gender were significantly associated with Wb Mf positivity. 
After controlling for age, gender and village of residence, the odds of being Wb Mf positive was 2.67 times higher 
in Mp positive individuals (95% CI [1.42-5.01]). Given the geographical overlap between Mp and Wb in Africa, a 
better understanding of the distribution and prevalence of Mp could assist national LF control programs in 
predicting areas of high Wb mf prevalence that may require closer surveillance. 
INTRODUCTION 
Lymphatic filariasis (LF) is a chronic neglected tropical disease that is endemic in 72 
countries worldwide, including Mali.1,2 Lymphatic filariasis is associated with significant 
morbidity due primarily to lymphedema and hydrocele1,3 and has been targeted by the World 
Health Organization and its partners for elimination by 2020.1 The strategies for elimination are 
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based on two pillars, community-based mass drug administration (MDA) to interrupt 
transmission through clearance of microfilaremia (Mf) over the lifespan of the adult worms (6 
years) and morbidity management (hydrocele and lymphedema).1 Known risk factors for 
Wuchereria bancrofti (Wb) infection include environmental,2,4 sociocultural, and demographic 
(age and gender) factors.5,6 For example, in Mali, the prevalence of Wb circulating antigen (Wb 
CAg), a marker of active infection, ranged from 18.6% in the south to 1% in the north, the latter 
being desertous and thereby ecologically less suitable for Wb transmission.7 These factors affect 
endemicity and thus impact control programs. 
Microfilaremia is the main factor that drives the endemicity level in a given area and can be 
used as a surrogate for transmission assessment before and during MDA. By definition, if 
microfilariae (mf) are found in the peripheral blood, fertile adults must be viable and drug 
distribution must continue if transmission is to be interrupted.6,8 Factors other than drug coverage 
may have an impact on Wb Mf load and thereby alter the efficacy of MDA at the individual or 
community level. These factors include spatial clustering, coincident infection with other 
organisms, bed net use and occupation.9–11 To determine the effect of these factors on Wb 
prevalence and Mf levels within a single transmission area, data obtained before an 
interventional study12 in two neighboring villages (Tieneguebougou and Bougoudiana) were 
compared. 
METHODS 
Study sites. 
The study was conducted in the villages of Tieneguebougou and Bougoudiana,  105 km 
northwest of Bamako, Mali (Figure 1). These villages are not endemic for onchocerciasis. They 
are in a northern savannah area with an average annual rainfall of 589.4 mm. The total 
population at the time of the data collection was 1,945 for Tieneguebougou and 991 for 
Bougoudiana. 
Ethical considerations. 
The study was approved by both the ethical review committee of the Faculty of Medicine, 
Pharmacy, and Dentistry at the University of Bamako (Bamako, Mali) and the Institutional 
Review Board of the National Institutes of Allergy and Infectious Diseases (Bethesda, MD). 
Before the launch of the study, community permission was obtained from village elders after a 
series of explanatory meetings. Individual written informed consent was obtained from all 
subjects (or from legal guardians for subjects less than 18 years of age). 
Study design. 
A cross-sectional study design was used to obtain data as part of the screening for 
participation in an interventional study of MDA dosing regimens (NCT00339417).12 All study 
activities were conducted at the primary school in Tieneguebougou or in two rooms provided by 
the chief of the village in Bougoudiana. Consenting participants underwent an extensive history 
and physical examination and blood collection. Data collected included demographics, related 
signs and symptoms of Wb infection, previous participation in MDA campaigns, and bed net 
utilization. 
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Parasitologic testing. 
Wuchereria bancrofti infection was defined by the presence of Wb Mf on a calibrated thick 
smear of blood collected between 10 PM and 2 AM13 or a positive test for circulating Wb Ag 
(TropBio, Townsville, Australia) by ELISA.14 For each participant, three Giemsa-stained slides, 
each containing 20 L of whole blood collected at night, were examined for the presence of Mf. 
Counting of Wb and Mansonella perstans (Mp) Mf was performed microscopically at 40 
magnification. Speciation was confirmed based on size and morphology at 100 magnification 
under oil-immersion. Each slide was read by two independent readers. A third reader was used to 
resolve discrepancies of  10%. The final parasite load reported for each participant was the 
average of the Mf counts obtained. Wuchereria bancrofti CAg was detected in serum by ELISA 
(TropBio) based on the manufacturer’s protocol. A value of > 32 Units/mL was considered 
positive. 
Mapping and spatial analysis. 
The geographical coordinates (latitude and longitude) of each participant’s household were 
determined using a GPS device. To examine the magnitude and geographical distribution of Wb 
Mf load throughout the two villages, the household coordinates and all related data were 
compiled in a database and mapped using the geographic information system (GIS) software 
ArcGIS 9.2 (Esri, Redlands, CA). Spatial analysis of Wb load was examined using ArcGIS 
Spatial Analyst and statistics tools (Esri). 
Statistical analysis. 
Unless stated otherwise, medians were used to describe central tendency. Differences 
between groups were assessed using the Mann–Whitney U test. Bivariate analyses was 
performed to explore the associations between Wb infection and each of the other variables 
including Mp infection, prior participation in MDA, the use of bed nets, age, gender, and villages 
of residence. Logistic regression was then performed to control for confounding factors. In this 
logistic regression, Wb Mf infection was the outcome of measure and Mp infection primary risk 
factor with age, gender, and village of residence as secondary cofactors. Spearman correlation 
was used to measure the relationship between two continuous variables. The Moran’s I statistic 
was used to test for spatial autocorrelation patterns, that is, clustered, dispersed, and random. 
RESULTS 
Of the 372 individuals included in the analyses, a total of 187 (50.27%) were Wb positive 
based on Wb CAg testing. Wuchereria bancrofti Mf were detectable in blood from 64 of the 187 
CAg-positive subjects (34.22%) (Table 1). There were few differences between the CAg-positive 
groups and CAg-negative groups, with the exception of age (45.5 years in the CAg-positive 
group versus 29 years in the CAg-negative group, P = 0.007) (Table 1) and Mp infection 
prevalence (62.56% in the CAg-positive group versus 56.9% in the CAg-negative group, P = 
0.0002). The prevalence of Mp Mf was also increased in the Wb Mf+ group (73.4%) compared 
with the Wb Mf group (56.9%) (P = 0.001, Fisher’s exact test) (Table 1). In contrast, gender 
distribution, median age, participation in either of the two previous MDA campaigns in the study 
villages, and bed net use were comparable between Wb Mf+ and Wb Mf individuals (Table 1). 
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In univariate and multivariate analysis, Mp status and village of residence were identified as 
significant risk factors for the presence of Wb Mf. Not only was Wb Mf load significantly 
increased in the Wb+Mp+ coinfected group as compared with the Wb+Mp monoinfected group 
(P = 0.0002, Mann–Whitney U test) (Figure 2), but there was a significant positive correlation 
between Wb and Mp Mf levels in coinfected subjects (P < 0.001, r = 0.25, Spearman correlation) 
(Figure 3). The geometric mean Wb Mf level in Tieneguebougou (2.45 mf/mL; 95% confidence 
interval [CI]: [1.45; 3.77]) was increased compared with that in Bougoudiana (0.17 mf/mL; 95% 
CI: [0.34–1.15]) (P < 0.001). In contrast, the geometric mean Mp levels were comparable in the 
two villages (11.11 mf/mL; 95% CI: [7.33; 16.59] in Tieneguebougou and 12 mf/mL; 95% CI: 
[7.91; 17.96] in Bougoudiana) (P = 0.76). After controlling for age, gender, and village of 
residence, the odds of being Wb Mf positive was  3 times greater if Mp Mf positivity was also 
present (OR = 2.67 95% CI: [1.62–5.36]) (Table 2). 
Despite comparable infection rates (as assessed by CAg positivity in Tieneguebougou and 
Bougoudiana 55.4% (107/195) and 44.9% (80/178), respectively; P = 0.05 Fisher’s exact test), 
village of residence was also significantly associated with Wb Mf status (OR = 2.52 [1.41–4.51]). 
This association was not due to differences in Mp Mf, age, gender, or bed net use between the 
two study villages (Table 3). Moreover, there was a relatively even distribution of Wb Mf 
positivity across the two villages studied with 23.2% (45/149) versus 10.7% (19/159) Wb Mf 
positive, respectively, and geospatial analyses failed to detect any systematic spatial association 
between Mf-positive and Mf-negative individuals (Moran’s I spatial statistic; MI = 0.01, Z 
score = 0.1, P > 0.05) (Figure 4). Although antifilarial drug use was not identified as a risk factor 
for Wb Mf positivity in the univariate or multivariate analyses, there was a small but statistically 
significantly higher frequency of antifilarial drug use in Bougoudiana (59.5% versus 47.4% in 
Tieneguebougou; P = 0.02) (Table 3). 
DISCUSSION 
Understanding the factors that affect Wb Mf at the individual and local levels can help 
identify regions within an endemic district that are likely to have higher local transmission and 
may require closer surveillance. The present study examined some of these factors in two 
neighboring villages in an area endemic for Wb with an overall CAg prevalence of > 50%. 
Despite similar infection prevalences (rates of Wb CAg positivity) between the two villages, Wb 
microfilarial prevalences were significantly different, suggesting a role for factors other than 
ecology in Wb Mf prevalence in this setting. Whereas village of residence, Mp Mf positivity, and 
age > 38 years were significantly associated with Wb mf positivity in univariate analysis, only 
Mp Mf and village of residence remained significant in multivariate analysis. Gender was not a 
significant risk factor for Wb Mf positivity in univariate analysis but proved significant in the 
multivariate analysis, consistent with prior data demonstrating an increased prevalence of Mf in 
males.15,16 
An association between Wb infection and Mp Mf at the individual level was reported 
previously in a different region of Mali17 but not seen in a similar study in Uganda.4 The reason 
for this discrepancy may be the presence of different strains of Mp in different parts of Africa, as 
was suggested in studies from Kenya.18,19 In fact, the Uganda Mp strains appear to have lost the 
Wolbachia endosymbiont, whereas in Mali, Gabon, and Cameroon, Mp has been demonstrated to 
contain Wolbachia, both directly by PCR and indirectly as evidenced by treatment response to 
doxycycline.20,21 
Page 5 of 13 
In the present study, Wb Mf load was increased in subjects with concomitant Mp infection 
and correlated with Mp Mf load at the individual level. A positive association between Mp and 
Wb Mf densities was also reported in the Ugandan study.4 Similar relationships have been seen 
in other filarial coinfections, including loiasis and onchocerciasis,22 suggesting common 
regulatory mechanisms controlling microfilarial numbers between species. 
Because both Mp and Wb are spread by insect vectors that bite unprotected skin, inhabitants 
of endemic areas who engage in activities that put them at increased risk for vector bites are at 
high risk of acquiring both Wb and Mp infection.4 This could lead to clustering of infection, as 
has been described in LF.18 Although Moran’s I spatial statistic failed to detect significant spatial 
correlation or clustering between Mp and Wb in this study, this could have been due to the 
relatively small sample size. 
Surprisingly, neither Wb infection rates nor Mf density were significantly reduced by prior 
MDA-based antifilarial drug treatment or bed net use, which has been shown to synergize with 
MDA in eliminating LF.17 Nevertheless, the significantly increased history of MDA participation 
in Bougoudiana as compared with Tieneguebougou is consistent with a role for antifilarial drug 
therapy in reducing Wb Mf levels at the community level. The lack of significance in the 
univariate and multivariate analysis may be due to the relatively small impact of two MDA 
rounds on LF Mf, as observed in a previous study in a highly endemic area in Mali where as 
many as six MDA rounds were required to decrease LF Mf to the recommended threshold levels 
for elimination.23 
In conclusion, in multivariate analysis, Wb Mf was associated with the village of residence, 
the presence of Mp Mf, and gender in two neighboring rural villages in Mali. Given the 
geographical overlap between Mp and Wb in Africa,18 a better understanding of the distribution 
and prevalence of Mp could assist national LF control programs in predicting areas of high Wb 
mf prevalence that may require closer surveillance. 
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FIGURE 1. Map of Koulikoro district with the two study villages indicated by black dots. The inset shows the 
location of the district (depicted by a black square) within the country of Mali. This figure appears in color at 
www.ajtmh.org. 
FIGURE 2. Wuchereria bancrofti (Wb) load among Mansonella perstans (Mp)-negative and Mp-positive subjects. 
Gray dot: Wb microfilaremia (Mf) for each monoinfected. Black dot: Wb Mf for each monoinfected. 
FIGURE 3. Correlation between Mansonella perstans and Wuchereria bancrofti microfilaremia loads within study 
subjects. 
FIGURE 4. Geographic distribution of Wuchereria bancrofti antigen (Wb Ag) and Mansonella perstans (Mp). (A) 
Spatial distribution of Wb Ag with gray dot the positive and white dot the negative, (B) spatial distribution of Wb 
microfilaremia (Mf) with gray dot the positive and white dot the negative, and (C) spatial distribution of Mp Mf 
with gray dot the positive and white dot the negative. 
TABLE 1 
Characteristics of the study population 
 Wb infected (CAg+) Wb uninfected (CAg) 
(N = 187) (N = 185) 
 Mf+ (N = 64) Mf (N = P values* CAg (N = P values† 
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123)  185)  
Median age (range) 45.5 (14–64) 41 (14–65) 0.33 29 (14–77) 0.007 
Male 47 (73.4%) 76 (61.8%) 0.07 112 (60.5%) 0.17 
Tieneguebougou 45 (70.3%) 62 (50.4%) 0.01 87 (47%) 0.06 
Bed net owner 27 (42.2%) 44 (35.8%) 0.2 65 (35.1%) 0.32 
Antifilarial drug use‡ 30 (46.9%) 69 (56.1%) 0.1 99 (53.5%) 0.49 
Mp positive 47 (73.4%) 70 (56.9%) 0.01 79 (42.7%) < 0.001 
CAg = circulating antigen; Mf = microfilaremia; Mp = Mansonella perstans; Wb = Wuchereria bancrofti. 
* Wb mf positive vs. microfilariae negative. 
† Wb-infected (CAg+) vs. Wb-uninfected (CAg) subjects. 
‡ Albendazole and ivermectin treatment during at least one of the two prior mass drug administration. 
 
 
 
TABLE 2 
Risk factors associated with Wuchereria bancrofti microfilaremia in Tieneguebougou and Bougoudiana 
Variables Category Univariate analysis Multivariate analysis 
Crude OR [95% CI] P values Adjusted OR [95% CI] P values 
Coinfection Mp negative Ref.    
Mp positive 2.95 [1.62–5.36] < 0.001 2.67 [1.42–5.01] 0.0021 
Age  38 years Ref.    
< 38 years 1.80 [1.03–3.13] 0.035 1.84 [0.99–3.42] 0.0522 
Gender Male Ref.    
Female 1.76 [0.96–3.21] 0.061 0.47 [0.24–0.91] 0.0257 
Village Tieneguebougou Ref.    
Bougoudiana 2.52 [1.41–4.51] 0.001 2.69 [1.48–4.91] 0.0012 
Protection measure No bed net owner Ref.    
Bed net owner 1.33 [0.76–2.30] 0.304   
No antifilarial drug use* Ref.    
Antifilarial drug use* 0.73 [0.42–1.26] 0.263   
CI = confidence interval; Mp = Mansonella perstans. 
* Albendazole and ivermectin treatment during at least one of the two prior mass drug administration. 
TABLE 3 
Risk factors distribution by village 
 Tieneguebougou (N = 194) Bougoudiana (N = 178) P values 
Median age (range) 37 (14–65) 38.5 (14–65) 0.45* 
Male 126 (64.9%) 109 (61.2%) 0.51† 
Bed net owner 65 (33.5%) 71 (39.8%) 0.23† 
Antifilarial drug use‡ 92 (47.4%) 106 (59.5%) 0.02† 
Mp positive 101 (52.1%) 96 (53.9%) 0.75† 
Mp = Mansonella perstans. 
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* Mann–Whitney U test. 
† Fisher’s exact test. 
‡ Albendazole and ivermectin treatment during at least one of the two prior mass drug administration. 
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